|
|
Volumn 9, Issue 12, 2010, Pages 903-906
|
|
First oral warfarin alternative approved in the US
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
APIXABAN;
BETRIXABAN;
CYTOCHROME P450 2C9;
DABIGATRAN ETEXILATE;
EDOXABAN;
LETAXABAN;
RIVAROXABAN;
UNCLASSIFIED DRUG;
WARFARIN;
XIMELAGATRAN;
YM 150;
ACUTE CORONARY SYNDROME;
ACUTE HEART INFARCTION;
AGING;
ANTICOAGULANT THERAPY;
BLOOD CLOT;
BRAIN HEMORRHAGE;
CLINICAL TRIAL;
DRUG APPROVAL;
DRUG CLEARANCE;
DYSPEPSIA;
GASTROINTESTINAL HEMORRHAGE;
HEART ATRIUM FIBRILLATION;
HEART FAILURE;
HEART INFARCTION;
HUMAN;
HYPERTENSION;
INCIDENCE;
INTERNATIONAL NORMALIZED RATIO;
PRESCRIPTION;
PREVALENCE;
PRIORITY JOURNAL;
SHORT SURVEY;
STROKE;
UNITED STATES;
VENOUS THROMBOEMBOLISM;
ANIMALS;
ANTICOAGULANTS;
ANTITHROMBIN PROTEINS;
BENZIMIDAZOLES;
CLINICAL TRIALS AS TOPIC;
DRUG APPROVAL;
DRUG DISCOVERY;
HUMANS;
PRODRUGS;
PYRIDINES;
UNITED STATES;
WARFARIN;
|
|
EID: 78649717192
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3322 Document Type: Short Survey |
|
Times cited : (17)
|
|
References (0)
|
